Table 1 Demographic profile of the study population.

From: Folylpolyglutamate synthase is a major determinant of intracellular methotrexate polyglutamates in patients with rheumatoid arthritis

 

(n = 271)

AE (−) group

AE (+) group

P value

(n = 188)

(n = 83)

Age (years)

60.4 ± 12.6

60.0 ± 13.2

61.4 ± 13.8

P = 0.464

No. of men/women

59/212

48/140

11/72

P = 0.031

Duration (months)

107.3 ± 96.0

103.0 ± 93.9

117.0 ± 98.2

P = 0.176

Dose of MTX (mg/week)

8.7 ± 3.1

9.5 ± 3.0

6.9 ± 2.5

P < 0.001

Stage (I/II/III/IV)

(90/61/46/74)

(68/42/31/47)

(22/19/15/27)

 

CRP (mg/dl)

0.22 ± 0.13

0.23 ± 0.35

0.19 ± 0.22

P = 0.942

ESR (mm/hour)

15.8 ± 13.3

15.4 ± 13.0

16.5 ± 15.6

P = 0.671

DAS28-ESR

2.29 ± 1.05

2.35 ± 1.09

2.17 ± 0.95

P = 0.227

CDAI

3.30 ± 4.26

3.80 ± 5.03

3.20 ± 4.88

P = 0.618

SDAI

5.51 ± 5.27

5.12 ± 6.74

5.14 ± 5.45

P = 0.881

BMI

22.0 ± 3.4

21.6 ± 3.6

22.6 ± 3.9

P = 0.889

BW(kg)

55.5 ± 11.2

56.4 ± 9.2

53.4 ± 10.8

P = 0.926

No. of patients using: Prednisolone

83(30.6%)

53(28.2%)

30(36.1%)

P = 0.195

Other DMARDs

51(18.8%)

24(12.8%)

27(32.5%)

P < 0.001

Biological agents

134(49.4%)

82(43.6%)

52(62.7%)

P < 0.001

  1. Data are the mean±SD, n  =  number of patients
  2. P values for comparison between the AE (−) and AE (+) groups were evaluated by the Mann-Whitney U test and Fisher’s exact test.
  3. MTX: methotrexate, stage: Steinblocker’s classification of progression, CRP: C-reactive protein, ESR: erythrocyte sedimentation rate, DAS: disease activity score, CDAI: clinical disease activity index, SDAI: simplified disease activity index, BMI: body mass index, DMARDs: disease-modifying anti-rheumatic drugs.
Back to article page